Funding Resources
Funding Overview
Funding Strategy
Funding Opportunities
Grant Mechanisms
Training & Career
Development
Contracts Management
Review Committees |
Research
Anticonvulsant Screening
Program
Clinical Research
Counterterrorism
Epilepsy Research Web
Neural Interfaces Program
NIH Roadmap Research
Parkinson's Web
Resources for Scientists
Stem Cell Research
Translational Research
Traumatic Brain Injury
(TBI) Research
Technology Transfer
Office
NINDS is part of the
National Institutes of
Health
In May 2002, the NINDS invited an independent committee to review and consider the data from the 5-year, multi-site study of "Tissue Plasminogen Activator for Acute Ischemic Stroke," published by the NINDS r-TPA Stroke Study Group in the New England Journal of Medicine, December 14, 1995. The study represents the first treatment for acute ischemic stroke, and the therapeutic agent t-PA was approved by the FDA for this usage in June of 1996. The NINDS asked that the committee "address whether there is concern that eligible stroke patients may not benefit from rt-PA given according to the protocol used in the (NINDS) trials, and whether any subgroup imbalances invalidate the trial as claimed by some of the critics."
The findings of the Review Committee are summarized in the following documents:
Note: Adobe Acrobat 5.0 or later is required to open these documents.
Last updated March 08, 2005